#news #biotech Protalix’ oral anti-TNF drug hits the mark in phase 2 ulcerative colitis trial

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Protalix’ oral anti-TNF drug hits the mark in phase 2 ulcerative colitis trial .If successful in further trials, OPRX-106 could mount a challenge in the market for injectable and infused TNF drugs, worth tens of billions of dollars a year.

from FierceBiotech: Biotech http://ift.tt/2p7CPY4